Neutrophil stunning by metoprolol reduces infarct size

Citations Over TimeTop 1% of 2017 papers

Abstract

The β1-adrenergic-receptor (ADRB1) antagonist metoprolol reduces infarct size in acute myocardial infarction (AMI) patients. The prevailing view has been that metoprolol acts mainly on cardiomyocytes. Here, we demonstrate that metoprolol reduces reperfusion injury by targeting the haematopoietic compartment. Metoprolol inhibits neutrophil migration in an ADRB1-dependent manner. Metoprolol acts during early phases of neutrophil recruitment by impairing structural and functional rearrangements needed for productive engagement of circulating platelets, resulting in erratic intravascular dynamics and blunted inflammation. Depletion of neutrophils, ablation of Adrb1 in haematopoietic cells, or blockade of PSGL-1, the receptor involved in neutrophil-platelet interactions, fully abrogated metoprolol's infarct-limiting effects. The association between neutrophil count and microvascular obstruction is abolished in metoprolol-treated AMI patients. Metoprolol inhibits neutrophil-platelet interactions in AMI patients by targeting neutrophils. Identification of the relevant role of ADRB1 in haematopoietic cells during acute injury and the protective role upon its modulation offers potential for developing new therapeutic strategies.

Related Papers

• → Cytochrome P450 2D6 phenotype and genotype in hypertensive patients on long-term therapy with metoprolol(2013)3 cited
• → [Effects of CYP2D6*10 on plasma trough concentration of metoprolol in patients with coronary artery disease].(2019)1 cited
• → The effect of impaired renal function on the pharmacokinetics of metoprolol after single administration of a metoprolol OROS system(1990)8 cited
• [Effect of metoprolol in patients with renal hypertension].(1988)
• Clinical Effect of Metoprolol on Elderly Patients with Chronic Heart Failure and its Safety(2007)